临床误诊误治2024，Vol.37Issue(3)：109-113,5.DOI:10.3969/j.issn.1002-3429.2024.03.022
贝伐珠单抗与GC化疗方案联合治疗晚期非小细胞肺癌的效果及药物经济学评价
Efficacy and Pharmacoeconomic Evaluation of Bevacizumab Combined with GC Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer
摘要
Abstract
Objective To explore the efficacy and pharmacoeconomic value of Bevacizumab combined with GC chem-otherapy regimen(Cisplatin +Gemcitabine)in the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 86 patients with advanced NSCLC treated from July 2020 to July 2022 were selected and divided into control group(n =43)and observation group(n =43)according to treatment plan.The control group was given GC chemotherapy,and the observation group was given Bevacizumab combined with GC chemotherapy.The efficacy,occurrence of toxic and side effects and blood biochemical indexes before and after treatment were compared between the two groups,and cost-effectiveness analy-sis was performed.Results The objective remission rate of 58.14%(25/43)and disease control rate of 93.02%(40/43)in the observation group were higher than those in the control group[32.56%(14/43)and 72.09%(31/43)](P<0.05).After 2 and 4 courses of treatment,the serum carcinoembryonic antigen,carbohydrate antigen 125,neuron specific enolase,vascular endothelial growth factor and basic fibroblast growth factor in observation group were lower than those in control group(P<0.05).There was no significant difference in the total incidence of toxic and side effects between the two groups(P>0.05).The total cost of observation group was higher than that of control group(P<0.05).The cost-effectiveness ratio(790.67)was lower than that of the control group(901.31),and sensitivity analysis showed that cost-effectiveness analysis was stable and reliable.Conclusion In the treatment of advanced NSCLC patients,Bevacizumab combined with GC chemo-therapy can downregulate the levels of tumor markers and vascular endothelial factors,and improve the efficacy,with obvious cost-effectiveness advantage.关键词
癌,非小细胞肺/贝伐珠单抗/GC化疗方案/癌胚抗原/糖类抗原125/神经元特异性烯醇化酶/血管内皮生长因子/成纤维细胞生长因子,碱性Key words
Carcinoma,non-small-cell lung/Bevacizumab/GC chemotherapy protocol/Carcinoembryonic antigen/Carbohydrate antigen 125/Neuronal specific enolase/Vascular endothelial growth factor/Fibroblast growth factor,basic分类
医药卫生引用本文复制引用
李亚利,乔廷廷,王雪..贝伐珠单抗与GC化疗方案联合治疗晚期非小细胞肺癌的效果及药物经济学评价[J].临床误诊误治,2024,37(3):109-113,5.基金项目
河北省卫生健康委员会医学科学研究计划项目(20231450) （20231450）
